GW Pharmaceuticals Plc has appointed Volker Knappertz as chief medical officer, reporting Chief Executive Officer Justin Gover and based at the company’s US headquarters in Carlsbad, California. It has also named Ben Whalley, previously professor of neuropharmacology at the University of Reading, to the newly created position of head of discovery research, based in the UK.
Dr Knappertz comes to GW Pharmaceuticals from Teva Pharmaceutical Industries Ltd where he led clinical development of multiple sclerosis, oncology and biosimilar products. Before that he held clinical and medical roles for central nervous system and cardiovascular disorders at Bayer AG and AstraZeneca Plc. Dr Knappertz holds an MD and a doctorate from the University of Cologne in Germany, and is a US board certified neurologist.
GW Pharmaceuticals announced the appointment on 15 May 2017
Copyright 2017 Evernow Publishing Ltd